Intravitreal Injection of Melphalan in the Treatment of Retinoblastoma with Vitreous Cavity Seeding.
Sun Ya-bin,Hui Peng,Kharbuja Punyara,Bi Ming-chao,Li Song-he,Teng Si-ying,Song E
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20123535
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:According to Reese-Ellsworth Classification for retinoblastoma, retinoblastoma with vitreous seeding is grade 5B with poor prognosis and was initially proposed for enucleation. Chemotherapy combined with local treatment for retinoblastoma has been proposed as conservative treatment.1 Because of the lack of blood supply to vitreous seeding, the chemotherapy drugs could not reach the vitreous body through blood-retinal barrier. This has been one of the important limiting factors in the treatment of children with retinoblastoma with vitreous seeding. Melphalan proved to be one of the 12 kinds of chemosensitive drugs for anti-retinoblastoma cell colony formation. 2 So, we used intravitreal melphalan injection to observe the therapeutic effect on the vitreous seeding. A 6-year old male child was admitted for whitening of left pupil for 6 years regularly and extensively pretreated with 4 courses of cryotherapy, 17 cycles of chemotherapy, two courses of selective intra-arterial chemotherapy, and laser photocoagulation during follow-up. In February 2011, he was found to have vitreous seeding of retinoblastoma. Ophthalmologic examination: visual acuity: Left eye: 0.1, intraocular pressure (IOP) 12 mmHg, the anterior segment was normal, three spots of whitish seeding was seen at the upper temporal region of vitreous cavity (Figure A) about 1/2 disc diameter (DD) × 1/2 DD, around 10 spots of grayish white satellite lesions, 5 DD above optical disc a yellow whitish tumor was seen, diameter of 6 DD × 5 DD, superficially calcified, avascular. From 2011 May to 2011 July, intravitreal injection of melphalan with anterior chamber puncture procedure (left) was done. It was given every two weeks for six times each dose of 20 μg/0.05 ml.Figure 1.: Fundus photograph. A: Three spots of seeding were seen at the upper temporal region of vitreous cavity (arrows). B: After 12 month follow up, no vitreous seeding was seen (arrow).After the 3rd injection, the seeding in vitreous cavity started decreasing. In all the six injection, the pathology report of aspirated aqueous fluid showed no metastatic tumor cells. After the 6th injection, visual acuity of left eye: 0.1, IOP: 11 mmHg, and no vitreous seeding was seen. Twelve months follow-up showed no sign of recurrence of vitreous seeding. The intravitreal injection was proceeded, according to the Kaneko3 surgical methods and dose. After six courses of intravitreal melphalan injection, 12 months follow-up did not show any recurrence of tumor, disappeared vitreous seeding and no new invasions were seen(Figure B), no significant change in vision. Thus, we can see that intravitreal injection of melphalan is safe and effective eradication of the vitreous seeding of retinoblastoma. Intravitreal injection of melphalan can inhibit tumor vascular supply to the fundus of retinoblastoma is not yet observed in this case, and large number of clinical trials and evidence are still needed for support.